Jounce Therapeutics

$10.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.78 (-6.63%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell JNCE and other stocks, options, and ETFs commission-free!

About JNCE

Jounce Therapeutics, Inc. Common Stock, also called Jounce Therapeutics, is a clinical stage immunotherapy company, which treat cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients. Its products pipeline include JTX-2011 (ICOS); JTX-4014 (PD-1); Lead Macrophage Program; Macrophage Targeting; T Reg; B Cells; and Stromal Targeting. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. The listed name for JNCE is Jounce Therapeutics, Inc. Common Stock.

CEO
Richard Murray
Employees
130
Headquarters
Cambridge, Massachusetts
Founded
2013
Market Cap
407.43M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
223.40K
High Today
$12.15
Low Today
$10.88
Open Price
$12.15
Volume
312.38K
52 Week High
$14.08
52 Week Low
$2.85

JNCE Earnings

-$0.82
$0.42
$1.66
$2.90
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
$0.22 per share
Actual
$0.86 per share
Replay Earnings Call

You May Also Like

HLNE
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure